Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

Immunotherapy has become a key therapeutic strategy in the treatment of many cancers. As
a result, research efforts have been aimed at understanding mechanisms of resistance to …

In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …

Compelling evidence have demonstrated that bulk tumors can arise from a unique subset of
cells commonly termed “cancer stem cells” that has been proposed to be a strong driving …

Trophoblast stem cells (TSCs) have recently been derived from human embryos and early-
first-trimester placenta; however, aside from ethical challenges, the unknown disease …

Among many anticancer drugs collectively named “targeted or molecular therapies”
epigenetic drugs are clearly promising. Differently from other agents targeting a single gene …

Despite the success of immune checkpoint inhibition (ICI) in treating cancer, patients with
triple-negative breast cancer (TNBC) often develop resistance to therapy, and the underlying …

Recent development of methods to discover and engineer therapeutic T‐cell receptors
(TCRs) or antibody mimics of TCRs, and to understand their immunology and …

During cancer initiation and progression, the somatic epigenome is broadly reprogrammed.
This reprogramming can be a consequence of several processes, including altered …

Histone deacetylase inhibitors (HDACi), including trichostatin A (TSA) and valproic acid, can
alter the acetylation of histones in chromatin and enhance gene transcription. Previously we …